Chairman and Chief Executive Officer, Abbott Laboratories
Appears in 1 story
Leading post-acquisition integration
Abbott Laboratories closed its $21 billion acquisition of Exact Sciences on March 23, making the maker of the Cologuard colorectal cancer screening test a wholly owned subsidiary of one of the world's largest healthcare companies. The all-cash deal, at $105 per share, passed through antitrust review without a second request from regulators—a sign of how little the two companies' product lines overlapped before this combination.
Updated May 30
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
